UroGen Pharma to Present at the Jefferies 2017 London Healthcare Conference

RA’ANANA, Israel and NEW YORK, Nov. 09, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conference in London, UK on Thursday, November 16, 2017 at 11:20 a.m. GMT (6:20 a.m. ET).

A live audio webcast of the presentation will be available by visiting the Investors section of the UroGen Pharma website at http://investors.urogen.com. An archived replay of the webcast will be available on the Company's website for two weeks following the live presentation.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (NASDAQ:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology.  The Company has developed RTGel™, a proprietary sustained release, hydrogel-based formulation for potentially improving therapeutic profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel™ and VesiGel™, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma and bladder cancer. UroGen Pharma is headquartered in Ra’anana, Israel and maintains a corporate office in New York City.

CONTACTS:

UroGen Pharma Ltd.
Gary Titus
Chief Financial Officer
[email protected]
646-768-9531

Or

Burns McClellan, Inc.
Steve Klass
[email protected]
212-213-0006